JP2018536624A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018536624A5 JP2018536624A5 JP2018514882A JP2018514882A JP2018536624A5 JP 2018536624 A5 JP2018536624 A5 JP 2018536624A5 JP 2018514882 A JP2018514882 A JP 2018514882A JP 2018514882 A JP2018514882 A JP 2018514882A JP 2018536624 A5 JP2018536624 A5 JP 2018536624A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- variable domain
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 143
- 239000012634 fragment Substances 0.000 claims 24
- 239000000427 antigen Substances 0.000 claims 23
- 102000036639 antigens Human genes 0.000 claims 23
- 108091007433 antigens Proteins 0.000 claims 23
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 6
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 5
- 208000032839 leukemia Diseases 0.000 claims 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 3
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 230000000527 lymphocytic effect Effects 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 210000004881 tumor cell Anatomy 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 206010057249 Phagocytosis Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims 2
- 102000044459 human CD47 Human genes 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 230000008782 phagocytosis Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 208000037540 Alveolar soft tissue sarcoma Diseases 0.000 claims 1
- 201000003076 Angiosarcoma Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 208000011594 Autoinflammatory disease Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 claims 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 claims 1
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 208000015021 Meningeal Neoplasms Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000032383 Soft tissue cancer Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 201000008736 Systemic mastocytosis Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 208000024519 eye neoplasm Diseases 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 claims 1
- 201000000052 gastrinoma Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 201000006866 hypopharynx cancer Diseases 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000022006 malignant tumor of meninges Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 201000008106 ocular cancer Diseases 0.000 claims 1
- 201000006958 oropharynx cancer Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000002511 pituitary cancer Diseases 0.000 claims 1
- 208000031223 plasma cell leukemia Diseases 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 206010042863 synovial sarcoma Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 201000011531 vascular cancer Diseases 0.000 claims 1
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562220725P | 2015-09-18 | 2015-09-18 | |
| US201562220691P | 2015-09-18 | 2015-09-18 | |
| US62/220,691 | 2015-09-18 | ||
| US62/220,725 | 2015-09-18 | ||
| US201562221852P | 2015-09-22 | 2015-09-22 | |
| US62/221,852 | 2015-09-22 | ||
| US201562232681P | 2015-09-25 | 2015-09-25 | |
| US62/232,681 | 2015-09-25 | ||
| US201562252171P | 2015-11-06 | 2015-11-06 | |
| US62/252,171 | 2015-11-06 | ||
| US201562263544P | 2015-12-04 | 2015-12-04 | |
| US62/263,544 | 2015-12-04 | ||
| US201662354592P | 2016-06-24 | 2016-06-24 | |
| US62/354,592 | 2016-06-24 | ||
| PCT/US2016/052383 WO2017049251A2 (en) | 2015-09-18 | 2016-09-17 | Therapeutic cd47 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018536624A JP2018536624A (ja) | 2018-12-13 |
| JP2018536624A5 true JP2018536624A5 (Direct) | 2019-12-05 |
| JP6885606B2 JP6885606B2 (ja) | 2021-06-16 |
Family
ID=58289729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018514882A Active JP6885606B2 (ja) | 2015-09-18 | 2016-09-17 | 治療用ｃｄ４７抗体 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10239945B2 (Direct) |
| EP (1) | EP3349787A4 (Direct) |
| JP (1) | JP6885606B2 (Direct) |
| CN (2) | CN116425875A (Direct) |
| AU (1) | AU2016324316B2 (Direct) |
| BR (1) | BR112018005322A2 (Direct) |
| CA (1) | CA2998644A1 (Direct) |
| IL (1) | IL258168A (Direct) |
| MX (1) | MX2018003374A (Direct) |
| NZ (1) | NZ740686A (Direct) |
| PH (1) | PH12018500515A1 (Direct) |
| RU (1) | RU2748401C2 (Direct) |
| UA (1) | UA126146C2 (Direct) |
| WO (1) | WO2017049251A2 (Direct) |
| ZA (1) | ZA201804326B (Direct) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2786083T3 (es) | 2012-12-12 | 2020-10-08 | Arch Oncology Inc | Anticuerpos terapéuticos CD47 |
| US9221908B2 (en) | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
| EA037654B1 (ru) | 2014-12-30 | 2021-04-27 | Селджин Корпорейшн | Анти-cd47-антитела и их применения |
| UA126146C2 (uk) | 2015-09-18 | 2022-08-25 | Арч Онколоджі, Інк. | Терапевтичне антитіло до cd47 |
| WO2018075960A1 (en) * | 2016-10-21 | 2018-04-26 | Tioma Therapeutics, Inc. | Therapeutic cd47 antibodies |
| WO2018175790A1 (en) * | 2017-03-22 | 2018-09-27 | Arch Oncology, Inc. | Combination therapy for the treatment of solid and hematological cancers |
| CN110770345A (zh) | 2017-04-14 | 2020-02-07 | 托尔奈公司 | 免疫调节多核苷酸、抗体缀合物及其使用方法 |
| CA3071860A1 (en) * | 2017-08-02 | 2019-02-07 | Phanes Therapeutics, Inc. | Anti-cd47 antibodies and uses thereof |
| EP4435008A2 (en) | 2017-08-18 | 2024-09-25 | Centessa Pharmaceuticals (UK) Limited | Binding agents |
| CN109422811A (zh) | 2017-08-29 | 2019-03-05 | 信达生物制药(苏州)有限公司 | 抗cd47抗体及其用途 |
| PL3697817T3 (pl) * | 2017-10-18 | 2023-01-23 | Forty Seven, Inc. | Terapia nowotworu złośliwego jajnika w oparciu o środek anty-cd47 |
| AU2018351007B2 (en) * | 2017-10-18 | 2024-05-16 | Forty Seven, LLC | Treatment of ovarian cancer with anti-CD47 and anti-PD-L1 |
| GB201720426D0 (en) * | 2017-12-07 | 2018-01-24 | Hummingbird Bioscience Pte Ltd | CD47 and BCMA antigen-binding molecules |
| WO2019086574A1 (en) * | 2017-11-01 | 2019-05-09 | Hummingbird Bioscience Holdings Pte. Ltd. | Cd47 and cd33 antigen-binding molecules |
| US20220298254A1 (en) | 2017-11-01 | 2022-09-22 | Hummingbird Bioscience Holdings Pte. Ltd. | Cd47 antigen-binding molecules |
| BR112020009805A2 (pt) | 2017-12-01 | 2020-10-13 | Seattle Genetics, Inc. | antígeno do mesmo que liga especificamente cd47 humano, o anticorpo ou fragmento de ligação a antígeno, sequência de ácidos nucleicos, vetor de expressão, célula hospedeira, métodos para produzir o anticorpo ou fragmento de ligação a antígeno, para tratar um câncer que expressa cd47 num indivíduo e para induzir apoptose de uma célula que expressa cd47, e, anticorpo mascarado |
| AU2018378529A1 (en) * | 2017-12-04 | 2020-06-18 | Beijing Hanmi Pharmaceutical Co., Ltd. | Anti-PD-L1/anti-CD47 bispecific antibody with structure like natural antibody and in form of heterodimer and preparation thereof |
| CN110144009B (zh) * | 2018-02-14 | 2020-01-21 | 上海洛启生物医药技术有限公司 | Cd47单域抗体及其用途 |
| WO2019179366A1 (en) * | 2018-03-20 | 2019-09-26 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-cd47 antibodies |
| CN110305212A (zh) * | 2018-03-27 | 2019-10-08 | 信达生物制药(苏州)有限公司 | 抗cd47抗体及其用途 |
| GB201804860D0 (en) * | 2018-03-27 | 2018-05-09 | Ultrahuman Two Ltd | CD47 Binding agents |
| CN110577597B (zh) | 2018-06-11 | 2021-10-22 | 康诺亚生物医药科技（成都）有限公司 | 一种阻断CD47和SIRPα相互作用的抗体 |
| CN108872569A (zh) * | 2018-06-19 | 2018-11-23 | 浠思（上海）生物技术有限公司 | 利用HTRF一步法筛选CD47/SIRP alpha阻断剂的方法 |
| CN112601544A (zh) * | 2018-07-05 | 2021-04-02 | 三钰生物科技股份有限公司 | 人类抗cd47抗体及其用途 |
| WO2020019135A1 (zh) * | 2018-07-23 | 2020-01-30 | 中国科学院微生物研究所 | 一种抗cd47抗体及其应用 |
| US20210324075A1 (en) * | 2018-08-13 | 2021-10-21 | Arch Oncology, Inc. | Therapeutic cd47 antibodies |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN113573728A (zh) * | 2018-11-14 | 2021-10-29 | 安驰肿瘤公司 | 治疗性SIRPα抗体 |
| CR20210310A (es) * | 2018-12-14 | 2021-11-24 | Boehringer Ingelheim Io Canada Inc | Anticuerpos antiperiostina y usos de estos |
| CN109550047A (zh) * | 2019-01-16 | 2019-04-02 | 中国药科大学 | 抗cd47抗体在制备防治心力衰竭的药物中的应用 |
| US20220144943A1 (en) * | 2019-02-08 | 2022-05-12 | Integrity Bioventures, Inc. | Anti-cd47 antibodies and uses thereof |
| EP3952886A1 (en) | 2019-04-10 | 2022-02-16 | Elevatebio Technologies, Inc | Flt3-specific chimeric antigen receptors and methods of using the same |
| EP3955963A4 (en) * | 2019-04-18 | 2023-05-31 | QLSF Biotherapeutics Inc. | ANTIBODIES TARGETING HUMAN CD47 |
| JP7561775B2 (ja) | 2019-06-07 | 2024-10-04 | エーエルエックス オンコロジー インコーポレイテッド | 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための方法及び試薬 |
| PH12021553197A1 (en) * | 2019-06-19 | 2022-11-07 | Lepu Biopharma Co Ltd | Anti-cd47 antibodies and uses thereof |
| CA3145791A1 (en) | 2019-07-16 | 2021-01-21 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
| CN112239507A (zh) | 2019-07-17 | 2021-01-19 | 鸿运华宁（杭州）生物医药有限公司 | ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用 |
| MX2022002505A (es) * | 2019-09-03 | 2022-06-02 | Akeso Biopharma Inc | Anticuerpo monoclonal anti-cd47 y uso del mismo. |
| WO2021046216A1 (en) * | 2019-09-03 | 2021-03-11 | Arch Oncology, Inc. | Methods for identifying biomarkers to predict treatment response |
| JP2022548484A (ja) * | 2019-09-16 | 2022-11-21 | サーフィス オンコロジー インコーポレイテッド | 抗ｃｄ３９抗体の組成物及び方法 |
| CA3153501A1 (en) | 2019-10-18 | 2021-04-22 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| CA3158622A1 (en) * | 2019-10-23 | 2021-04-29 | Arch Oncology, Inc. | Combination therapy for the treatment of solid and hematological cancers |
| CN114599681B (zh) | 2019-10-25 | 2024-01-09 | 上海药明生物技术有限公司 | 新型抗cd47抗体及其用途 |
| WO2021087064A1 (en) | 2019-10-31 | 2021-05-06 | Forty Seven, Inc. | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| BR112022009723A2 (pt) | 2019-12-17 | 2022-08-09 | Pfizer | Anticorpos específicos para cd47, pd-l1, e usos dos mesmos |
| EP4445902A3 (en) | 2019-12-24 | 2024-12-18 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
| MX2022009947A (es) | 2020-02-14 | 2022-11-07 | Jounce Therapeutics Inc | Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos. |
| EP4110830A4 (en) | 2020-02-28 | 2024-09-11 | Tallac Therapeutics, Inc. | TRANSGLUTAMINASE-MEDIATED CONJUGATION |
| US20240067738A1 (en) * | 2020-03-18 | 2024-02-29 | Elanco Us Inc. | Anti-il4 receptor antibodies for veterinary use |
| CN115916963A (zh) | 2020-03-27 | 2023-04-04 | 门德斯有限公司 | 白血病来源的经修饰细胞用于增强过继性细胞治疗的效力的离体用途 |
| AR121805A1 (es) * | 2020-04-10 | 2022-07-13 | Hutchison Medipharma Ltd | Anticuerpo anti-cd47 y usos del mismo |
| JP2023531678A (ja) | 2020-06-22 | 2023-07-25 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 加齢筋肉、萎縮性筋肉、または異栄養性筋肉の処置のためのｔｓｐ－１阻害物質 |
| KR20230033647A (ko) | 2020-06-30 | 2023-03-08 | 멘두스 비.브이. | 난소암 백신에서 백혈병 유래 세포의 용도 |
| CN114057876B (zh) * | 2020-07-31 | 2025-03-21 | 百奥泰生物制药股份有限公司 | Cd47抗体及其应用 |
| WO2022120286A1 (en) | 2020-12-06 | 2022-06-09 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| WO2022190058A1 (en) | 2021-03-12 | 2022-09-15 | Dcprime B.V. | Methods of vaccination and use of cd47 blockade |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| US20240190993A1 (en) | 2021-04-14 | 2024-06-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method to improve the anti-tumoral activity of macrophages |
| KR20240023629A (ko) | 2021-06-23 | 2024-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| EP4359411A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CR20230585A (es) | 2021-06-23 | 2024-02-19 | Gilead Sciences Inc | Compuestos Moduladores de Diacilglicerol Quinasa. |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2023278778A1 (en) * | 2021-06-30 | 2023-01-05 | Ohio State Innovation Foundation | Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-cd47-sirpα therapeutic agent |
| CN115925940A (zh) * | 2021-08-24 | 2023-04-07 | 上海鑫湾生物科技有限公司 | 特异性结合cd47的抗体、其重组溶瘤病毒及其用途 |
| TWI857377B (zh) | 2021-10-28 | 2024-10-01 | 美商基利科學股份有限公司 | 嗒-3(2h)-酮衍生物 |
| JP7787991B2 (ja) | 2021-10-29 | 2025-12-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｄ７３化合物 |
| CA3237577A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CN118488946A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| EP4479084A1 (en) | 2022-02-14 | 2024-12-25 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
| US12358887B2 (en) | 2022-03-17 | 2025-07-15 | Gilead Sciences, Inc. | IKAROS Zinc Finger Family degraders and uses thereof |
| WO2023183313A1 (en) | 2022-03-22 | 2023-09-28 | Sana Biotechnology, Inc. | Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods |
| US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| JP2025513258A (ja) | 2022-04-21 | 2025-04-24 | ギリアード サイエンシーズ， インコーポレイテッド | Ｋｒａ ｇ１２ｄ調節化合物 |
| IL317958A (en) | 2022-07-01 | 2025-02-01 | Gilead Sciences Inc | CD73 compounds |
| JP2025523043A (ja) | 2022-07-12 | 2025-07-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖ免疫原性ポリペプチド及びワクチン、並びにその使用 |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN120882725A (zh) | 2023-04-11 | 2025-10-31 | 吉利德科学公司 | Kras调节化合物 |
| AU2024259556A1 (en) | 2023-04-21 | 2025-10-23 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20250100998A1 (en) | 2023-07-26 | 2025-03-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025024663A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| CN120714022A (zh) * | 2024-03-27 | 2025-09-30 | 康方汇科(上海)生物有限公司 | 药物组合及用途 |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE143052T1 (de) | 1986-07-07 | 1996-10-15 | Centocor Inc | Chimärisches murine-mensch-immunoglobulin, spezifisch für tumorassoziertes 17-1a antigen |
| RU2212413C2 (ru) | 1997-09-11 | 2003-09-20 | Чугаи Сейяку Кабусики Кайся | Моноклональное антитело, полученное с помощью интегринассоциированного белка, его фрагмент fab, fab' или f(ab')2, гибридома, продуцирующая моноклональное антитело (вариант), антилейкемическое средство |
| US7531643B2 (en) | 1997-09-11 | 2009-05-12 | Chugai Seiyaku Kabushiki Kaisha | Monoclonal antibody inducing apoptosis |
| CA2226962A1 (en) | 1998-02-16 | 1999-08-16 | Marie Sarfati | Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection |
| DE19813759C1 (de) | 1998-03-27 | 1999-07-15 | Gsf Forschungszentrum Umwelt | Verfahren zur Induktion einer durch NK-Zellen vermittelten Immunantwort |
| AU2940900A (en) * | 1999-03-10 | 2000-09-28 | Chugai Seiyaku Kabushiki Kaisha | Single-stranded fv inducing apoptosis |
| US7696325B2 (en) | 1999-03-10 | 2010-04-13 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide inducing apoptosis |
| AU5627000A (en) | 1999-06-21 | 2001-02-05 | Inkine Pharmaceutical Company, Inc. | Angiocidin: a CYS-SER-VAL-THR-CYS-GLY specific tumor cell adhesion receptor |
| AU6698900A (en) | 1999-07-16 | 2001-02-05 | Agricultural Research Service | Live recombinant vaccine against avian leukosis virus using a marek's disease virus (mdv) virus as vector |
| US20010041670A1 (en) | 1999-12-06 | 2001-11-15 | Ronit Simantov | Thrombospondin-binding region of histidine-rich glycoprotein and method of use |
| AU2002315052A1 (en) * | 2001-05-15 | 2002-11-25 | Emory University | Polynucleotides and polypeptides relating to the modulation of sirp alpha-cd47 |
| US20050074457A1 (en) | 2001-12-12 | 2005-04-07 | Adeela Kamal | Assays and implements for determining and modulating hsp90 binding activity |
| US20040213792A1 (en) | 2003-04-24 | 2004-10-28 | Clemmons David R. | Method for inhibiting cellular activation by insulin-like growth factor-1 |
| JP4637749B2 (ja) | 2003-11-11 | 2011-02-23 | 中外製薬株式会社 | ヒト化抗ｃｄ４７抗体 |
| BRPI0515113A (pt) | 2004-09-10 | 2008-07-01 | Wyeth Corp | anticorpos anti-5t4 humanizados e conjugados de anticorpo anti-5t4/caliqueamicina |
| JP2007008895A (ja) | 2005-07-04 | 2007-01-18 | Chugai Pharmaceut Co Ltd | 抗ｃｄ４７抗体とインテグリンリガンドとの併用 |
| US7514229B2 (en) | 2005-09-29 | 2009-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for diagnosing and evaluating treatment of blood disorders |
| PL1994055T3 (pl) | 2006-03-10 | 2015-02-27 | Wyeth Llc | Przeciwciała anty-5T4 i ich zastosowanie |
| WO2008043072A2 (en) | 2006-10-05 | 2008-04-10 | Biogen Idec Inc. | Cd80 antagonists for treating neoplastic disorders |
| EP3424950A1 (en) | 2006-10-06 | 2019-01-09 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Prevention of tissue ischemia, related methods and compositions |
| AU2014201010B2 (en) * | 2008-01-15 | 2016-03-03 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for manipulating phagocytosis mediated by CD47 |
| DK2242512T3 (en) | 2008-01-15 | 2016-06-06 | Univ Leland Stanford Junior | Method for manipulating phagocytosis mediated by CD47 |
| EP3722317B1 (en) | 2008-01-15 | 2024-08-07 | The Board of Trustees of the Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| CN104548091A (zh) | 2008-02-11 | 2015-04-29 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
| KR101604515B1 (ko) * | 2008-03-14 | 2016-03-17 | 알러간, 인코포레이티드 | 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정 |
| DK3031825T3 (da) * | 2008-03-14 | 2019-10-28 | Allergan Inc | Immunbaserede aktivitetsassays for botulinum-toxin serotype a |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| CA2732102C (en) | 2008-08-07 | 2018-01-02 | Jeffrey S. Isenberg | Radioprotectants targeting thrombospondin-1 and cd47 |
| WO2011034969A1 (en) | 2009-09-15 | 2011-03-24 | The Board Of Trustees Of The Leland Stanford Junior University | Synergistic anti-cd47 therapy for hematologic cancers |
| WO2011083140A1 (en) * | 2010-01-08 | 2011-07-14 | Ablynx Nv | Immunoglobulin single variable domain directed against human cxcr4 |
| EP2526118A4 (en) | 2010-01-21 | 2013-11-13 | Immunogen Inc | COMPOSITIONS AND METHOD FOR THE TREATMENT OF EGG CANCER |
| ES2937174T3 (es) | 2010-05-14 | 2023-03-24 | Univ Leland Stanford Junior | Anticuerpos monoclonales humanizados y quiméricos para CD47 |
| US9243057B2 (en) * | 2010-08-31 | 2016-01-26 | The Regents Of The University Of California | Antibodies for botulinum neurotoxins |
| US20140271683A1 (en) | 2010-12-21 | 2014-09-18 | The Board Of Trustees Of The Leland Stanford Junior University | Therapeutic and Diagnostic Methods for Manipulating Phagocytosis Through Calreticulin and Low Density Lipoprotein-Related Receptor |
| CN104271757B (zh) | 2012-02-06 | 2020-06-09 | 印希彼有限公司 | Cd47抗体及其使用方法 |
| US20140140989A1 (en) | 2012-02-06 | 2014-05-22 | Inhibrx Llc | Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof |
| US20140294765A1 (en) | 2012-06-21 | 2014-10-02 | Compugen Ltd. | Lsr antibodies, and uses thereof for treatment of cancer |
| ES2784631T3 (es) * | 2012-12-03 | 2020-09-29 | Novimmune Sa | Anticuerpos anti-CD47 y métodos de uso de los mismos |
| US9221908B2 (en) | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
| ES2786083T3 (es) | 2012-12-12 | 2020-10-08 | Arch Oncology Inc | Anticuerpos terapéuticos CD47 |
| EP2953643B1 (en) * | 2013-02-06 | 2023-02-22 | Inhibrx, Inc. | Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof |
| CN112245586A (zh) | 2013-03-15 | 2021-01-22 | 小利兰·斯坦福大学托管委员会 | 用于实现治疗有效剂量的抗cd47剂的方法 |
| CN103665165B (zh) * | 2013-08-28 | 2016-02-24 | 江苏匡亚生物医药科技有限公司 | 一种靶向人CD47-SIRPα信号通路的双特异性抗体及其制备方法和用途 |
| MX2015014724A (es) | 2013-12-31 | 2016-06-02 | Dev Center Biotechnology | Anticuerpos anti-factor de crecimiento endotelial vascular (vegf) y uso de los mismos. |
| UA126146C2 (uk) | 2015-09-18 | 2022-08-25 | Арч Онколоджі, Інк. | Терапевтичне антитіло до cd47 |
| US10946042B2 (en) | 2015-12-01 | 2021-03-16 | The Trustees Of The University Of Pennsylvania | Compositions and methods for selective phagocytosis of human cancer cells |
| WO2018075960A1 (en) | 2016-10-21 | 2018-04-26 | Tioma Therapeutics, Inc. | Therapeutic cd47 antibodies |
| WO2018175790A1 (en) | 2017-03-22 | 2018-09-27 | Arch Oncology, Inc. | Combination therapy for the treatment of solid and hematological cancers |
| US20190309066A1 (en) | 2017-03-22 | 2019-10-10 | Arch Oncology, Inc. | Combination therapy for the treatment of solid and hematological cancers |
-
2016
- 2016-09-17 UA UAA201808714A patent/UA126146C2/uk unknown
- 2016-09-17 CA CA2998644A patent/CA2998644A1/en not_active Withdrawn
- 2016-09-17 EP EP16847511.9A patent/EP3349787A4/en not_active Withdrawn
- 2016-09-17 JP JP2018514882A patent/JP6885606B2/ja active Active
- 2016-09-17 CN CN202211086845.8A patent/CN116425875A/zh not_active Withdrawn
- 2016-09-17 CN CN201680062144.7A patent/CN108348589B/zh not_active Withdrawn - After Issue
- 2016-09-17 WO PCT/US2016/052383 patent/WO2017049251A2/en not_active Ceased
- 2016-09-17 MX MX2018003374A patent/MX2018003374A/es unknown
- 2016-09-17 AU AU2016324316A patent/AU2016324316B2/en not_active Revoked
- 2016-09-17 BR BR112018005322-8A patent/BR112018005322A2/pt not_active Application Discontinuation
- 2016-09-17 RU RU2018124859A patent/RU2748401C2/ru active
- 2016-09-17 NZ NZ740686A patent/NZ740686A/en not_active IP Right Cessation
-
2017
- 2017-11-21 US US15/820,054 patent/US10239945B2/en active Active
-
2018
- 2018-03-09 PH PH12018500515A patent/PH12018500515A1/en unknown
- 2018-03-15 IL IL258168A patent/IL258168A/en unknown
- 2018-06-27 ZA ZA2018/04326A patent/ZA201804326B/en unknown
-
2019
- 2019-02-08 US US16/271,513 patent/US10844124B2/en active Active
-
2020
- 2020-10-29 US US17/084,156 patent/US20210070865A1/en not_active Abandoned